Metropolis Healthcare Limited

Metropolis Healthcare reported a robust Q2 FY26, with Group revenue growing 23% year-over-year and organic revenue increasing by 12%. This growth was accompanied by a 60 basis points year-over-year improvement in organic EBITDA margin, reaching 26.8%. The company's TruHealth and Specialty segments were key drivers, growing 21% and 15% respectively on an organic basis, contributing to the overall positive performance.

The company is prioritizing organic growth and the successful integration of recent acquisitions, including Core Diagnostics, DAPIC, and Scientific Pathology. While integration efforts are progressing smoothly, management noted that the 'clean-up' of acquired businesses can impact short-term revenue. However, this process is crucial for setting a strong foundation for faster future growth. No new acquisitions are planned for the next 6-9 months, with a clear focus on leveraging existing assets and driving internal efficiencies.

Metropolis continues to expand its network, adding approximately 200 collection centers in H1 FY26 and planning another 300 in H2. The target is to increase collection centers per lab from the current 20-22 to 30 within 12-18 months, primarily through a franchised model to optimize profitability. Digital initiatives, including new consumer and partner apps, middleware auto-authorization, and AI call quality monitoring, are enhancing customer experience and operational efficiency, contributing to improved turnaround times and material efficiency.

Core Diagnostics, acquired for its genomics-based platform, is showing margin improvement, moving from 2-3% in Q1 FY26 to mid-to-high single-digit in Q2 FY26, with a target to reach close to double-digit by year-end. The B2C segment contributed 59% of organic revenue with 11% growth, while B2B accounted for 41% with 14% growth, driven by an increase in both patient volumes and realizations. The North region now contributes 19% of overall revenue, largely due to recent acquisitions.

The radiology segment remains very small for Metropolis, contributing a low single-digit percentage to revenue. However, the company is expanding basic radiology services (ECG, X-ray, ultrasound) across 35 centers in 5 cities. Metropolis is also closely tracking GLP-1 therapy developments, anticipating a long-term structural opportunity for diagnostic monitoring due to the need for regular testing, though no significant traction is visibly impacting growth yet.

The competitive environment is stable, with no major new entrants or price war escalation observed. Management notes a natural consolidation trend in the market, where smaller unorganized labs struggle due to rising compliance, technology, and quality requirements. This trend favors organized players like Metropolis, which is well-positioned with its brand equity, clinician trust, and superior quality standards, leading to increased patient and doctor retention.